ProCE Banner Activity

Frequently Asked Questions: Expanding the Spectrum of HER2 Positivity in Advanced Breast Cancer With T-DXd

Clinical Thought

Read experts’ answers to healthcare professionals’ questions on the optimal use and management of adverse events with the antibody–drug conjugate T-DXd in patients with HER2-low advanced breast cancer.

Released: February 13, 2023

Expiration: February 12, 2024

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca Pharmaceuticals

Daiichi Sankyo, Inc.

Disclosure

Nadia Harbeck, MD, PhD: consultant: AstraZeneca, Daiichi-Sankyo, Lilly, MDS, Novartis, Pierre Fabre, Pfizer, Roche, Sandoz/Hexal, Seagen; fees for non-CME/CE services: AstraZeneca, Daiichi-Sankyo, Lilly, MDS, Novartis, Pfizer, Pierre Fabre, Roche, Seagen.

Komal Jhaveri, MD: consultant/advisor/speaker: AbbVie, AstraZeneca, Blueprint Medicine, Bristol-Myers Squibb, Daiichi Sankyo, Eisai, Genentech/Roche, Gilead Sciences, Jounce Therapeutics, Lilly/Loxo Oncology, Menarini/Stemline, Novartis, Olema, Pfizer, Seagen, Sun Pharma, Taiho Oncology; researcher: AstraZeneca, Context Therapeutics, Debio, Genentech/Roche, Gilead Sciences, Lilly/Loxo, Merck, Novartis, Pfizer, Puma Biotech, Zymeworks.

Heather McArthur, MD, MPH: advisor: AstraZeneca, Bristol-Myers Squibb, Crown Bioscience, Daiichi Sankyo, Gilead Sciences, Immunomedics, Lilly, Merck, Pfizer, Puma Biotech, Seagen; researcher (paid to institution): Bristol-Myers Squibb, Merck.

Format

This program is made available online.